394 related articles for article (PubMed ID: 28136017)
1. The impact of trisulfide modification of antibodies on the properties of antibody-drug conjugates manufactured using thiol chemistry.
Liu R; Chen X; Dushime J; Bogalhas M; Lazar AC; Ryll T; Wang L
MAbs; 2017 Apr; 9(3):490-497. PubMed ID: 28136017
[TBL] [Abstract][Full Text] [Related]
2. Sensitive ELISA Method for the Measurement of Catabolites of Antibody-Drug Conjugates (ADCs) in Target Cancer Cells.
Salomon PL; Singh R
Mol Pharm; 2015 Jun; 12(6):1752-61. PubMed ID: 25738394
[TBL] [Abstract][Full Text] [Related]
3. Effects of Drug-Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody-Maytansinoid Conjugates.
Sun X; Ponte JF; Yoder NC; Laleau R; Coccia J; Lanieri L; Qiu Q; Wu R; Hong E; Bogalhas M; Wang L; Dong L; Setiady Y; Maloney EK; Ab O; Zhang X; Pinkas J; Keating TA; Chari R; Erickson HK; Lambert JM
Bioconjug Chem; 2017 May; 28(5):1371-1381. PubMed ID: 28388844
[TBL] [Abstract][Full Text] [Related]
4. Practical approaches for overcoming challenges in heightened characterization of antibody-drug conjugates with new methodologies and ultrahigh-resolution mass spectrometry.
Friese OV; Smith JN; Brown PW; Rouse JC
MAbs; 2018 Apr; 10(3):335-345. PubMed ID: 29393747
[TBL] [Abstract][Full Text] [Related]
5. Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates.
Erickson HK; Widdison WC; Mayo MF; Whiteman K; Audette C; Wilhelm SD; Singh R
Bioconjug Chem; 2010 Jan; 21(1):84-92. PubMed ID: 19891424
[TBL] [Abstract][Full Text] [Related]
6. Trisulfide modification impacts the reduction step in antibody-drug conjugation process.
Cumnock K; Tully T; Cornell C; Hutchinson M; Gorrell J; Skidmore K; Chen Y; Jacobson F
Bioconjug Chem; 2013 Jul; 24(7):1154-60. PubMed ID: 23713462
[TBL] [Abstract][Full Text] [Related]
7. Statistics of the distribution of the abundance of molecules with various drug loads in maytansinoid antibody-drug conjugates.
Goldmacher VS; Amphlett G; Wang L; Lazar AC
Mol Pharm; 2015 Jun; 12(6):1738-44. PubMed ID: 25635630
[TBL] [Abstract][Full Text] [Related]
8. A rapid on-line method for mass spectrometric confirmation of a cysteine-conjugated antibody-drug-conjugate structure using multidimensional chromatography.
Birdsall RE; Shion H; Kotch FW; Xu A; Porter TJ; Chen W
MAbs; 2015; 7(6):1036-44. PubMed ID: 26305867
[TBL] [Abstract][Full Text] [Related]
9. Conformation and dynamics of interchain cysteine-linked antibody-drug conjugates as revealed by hydrogen/deuterium exchange mass spectrometry.
Pan LY; Salas-Solano O; Valliere-Douglass JF
Anal Chem; 2014 Mar; 86(5):2657-64. PubMed ID: 24512515
[TBL] [Abstract][Full Text] [Related]
10. A native SEC-MS workflow and validation for analyzing drug-to-antibody ratio and drug load distribution in cysteine-linked antibody-drug conjugates.
Wu G; Yu C; Yin S; Du J; Zhang Y; Fu Z; Wang L; Wang J
J Chromatogr B Analyt Technol Biomed Life Sci; 2024 Jul; 1241():124167. PubMed ID: 38823148
[TBL] [Abstract][Full Text] [Related]
11. The Properties of Cysteine-Conjugated Antibody-Drug Conjugates Are Impacted by the IgG Subclass.
Datta-Mannan A; Choi H; Stokell D; Tang J; Murphy A; Wrobleski A; Feng Y
AAPS J; 2018 Sep; 20(6):103. PubMed ID: 30255287
[TBL] [Abstract][Full Text] [Related]
12. Characterization of Cysteinylation and Trisulfide Bonds in a Recombinant Monoclonal Antibody.
Kita A; Ponniah G; Nowak C; Liu H
Anal Chem; 2016 May; 88(10):5430-7. PubMed ID: 27115984
[TBL] [Abstract][Full Text] [Related]
13. Design of Coltuximab Ravtansine, a CD19-Targeting Antibody-Drug Conjugate (ADC) for the Treatment of B-Cell Malignancies: Structure-Activity Relationships and Preclinical Evaluation.
Hong EE; Erickson H; Lutz RJ; Whiteman KR; Jones G; Kovtun Y; Blanc V; Lambert JM
Mol Pharm; 2015 Jun; 12(6):1703-16. PubMed ID: 25856201
[TBL] [Abstract][Full Text] [Related]
14. Influence of disulfide bond isoforms on drug conjugation sites in cysteine-linked IgG2 antibody-drug conjugates.
Liu-Shin L; Fung A; Malhotra A; Ratnaswamy G
MAbs; 2018; 10(4):583-595. PubMed ID: 29436897
[TBL] [Abstract][Full Text] [Related]
15. Innovative native MS methodologies for antibody drug conjugate characterization: High resolution native MS and IM-MS for average DAR and DAR distribution assessment.
Debaene F; Boeuf A; Wagner-Rousset E; Colas O; Ayoub D; Corvaïa N; Van Dorsselaer A; Beck A; Cianférani S
Anal Chem; 2014 Nov; 86(21):10674-83. PubMed ID: 25270580
[TBL] [Abstract][Full Text] [Related]
16. Analysis of ADCs by Native Mass Spectrometry.
Hernandez-Alba O; Ehkirch A; Beck A; Cianférani S
Methods Mol Biol; 2020; 2078():197-211. PubMed ID: 31643058
[TBL] [Abstract][Full Text] [Related]
17. [The Characterization of Drug-to-Antibody Ratio and Isoforms of ADCs Using LC and MS Technologies].
Iizuka R; Kotch F; Xu A; Porter T; Shion H; Birdsall R; Chen W
Yakugaku Zasshi; 2017; 137(5):525-528. PubMed ID: 28458283
[TBL] [Abstract][Full Text] [Related]
18. Structural Characterization of a Monoclonal Antibody-Maytansinoid Immunoconjugate.
Luo Q; Chung HH; Borths C; Janson M; Wen J; Joubert MK; Wypych J
Anal Chem; 2016 Jan; 88(1):695-702. PubMed ID: 26629796
[TBL] [Abstract][Full Text] [Related]
19. Understanding How the Stability of the Thiol-Maleimide Linkage Impacts the Pharmacokinetics of Lysine-Linked Antibody-Maytansinoid Conjugates.
Ponte JF; Sun X; Yoder NC; Fishkin N; Laleau R; Coccia J; Lanieri L; Bogalhas M; Wang L; Wilhelm S; Widdison W; Pinkas J; Keating TA; Chari R; Erickson HK; Lambert JM
Bioconjug Chem; 2016 Jul; 27(7):1588-98. PubMed ID: 27174129
[TBL] [Abstract][Full Text] [Related]
20. Custom-Designed Affinity Capture LC-MS F(ab')2 Assay for Biotransformation Assessment of Site-Specific Antibody Drug Conjugates.
Su D; Ng C; Khosraviani M; Yu SF; Cosino E; Kaur S; Xu K
Anal Chem; 2016 Dec; 88(23):11340-11346. PubMed ID: 27779866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
